Source comparison
MOTS-c for Longevity Optimization: Comparison
MOTS-c AMPK activation, mitochondrial signaling, nuclear transcription via ATIC binding +18–22% improvement in clamp studies; sustained 48–72 hours post-dose Direct enhancement of mitochondrial respiration, ROS modulation, calcium handling Early-phase human tr
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation, mitochondrial signaling, nuclear transcription via ATIC binding
- +18–22% improvement in clamp studies; sustained 48–72 hours post-dose
- Direct enhancement of mitochondrial respiration, ROS modulation, calcium handling
- Early-phase human trials + robust animal models
- Requires prescription or research sourcing; subcutaneous injection 3x/week
- Most mechanistically targeted peptide for metabolic aging; short half-life but long signaling window makes it practical for intermittent dosing
- Metformin
- AMPK activation, Complex I inhibition in mitochondria
- +10–15% in diabetic populations; minimal effect in metabolically healthy individuals
- Indirect via AMPK; some ROS reduction but also impairs beneficial mitochondrial adaptation
- Decades of human data in diabetes; limited longevity RCTs
- OTC or prescription depending on jurisdiction; oral daily dosing
- Proven metabolic benefits in insulin-resistant populations; longevity data in healthy individuals is speculative; may blunt exercise adaptations
- NAD+ Precursors (NMN/NR)
- Increase NAD+ availability for sirtuins, PARP, mitochondrial enzymes
- Minimal direct effect; indirect via improved mitochondrial ATP production
- Supports mitochondrial enzyme function; does not address ROS or calcium handling
- Mixed human results; some trials show no benefit in healthy adults
- Widely available as supplements; oral daily dosing
- Addresses NAD+ decline but doesn't restore mitochondrial signaling coordination; most effective in NAD+-depleted states (age, metabolic disease)
- Rapamycin
- mTOR inhibition, autophagy induction
- Worsens insulin sensitivity acutely (mTOR required for insulin signaling); may improve long-term via autophagy
- Enhances mitophagy (removal of damaged mitochondria) but impairs mitochondrial biogenesis during treatment
- Strong animal longevity data; human longevity trials ongoing
- Prescription required; typically pulsed weekly to minimize side effects
- Potent autophagy inducer; trade-off between acute metabolic impairment and long-term cellular cleanup; not suitable for individuals prioritizing metabolic performance
- Caloric Restriction (20–30%)
- Reduced insulin/IGF-1 signaling, AMPK activation, autophagy
- +20–40% improvement in insulin sensitivity in overweight/obese; less in lean individuals
- Triggers mitochondrial biogenesis and stress resistance pathways
- Decades of animal data; human trials show benefits but compliance is low
- Free but requires sustained willpower and metabolic adaptation period
- Gold standard for longevity mechanisms; MOTS-c may replicate several CR benefits without dietary restriction; CR difficult to sustain long-term